Edward Arrowsmith

1.9k citations

60 papers · 1.2k indexed · h-index 18

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 5%
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes

Papers in ⓘ

Oncology 30
- Cancer Immunotherapy and Biomarkers 15
- Colorectal Cancer Treatments and Studies 5
Hematology 12
- Multiple Myeloma Research and Treatments 11

Co-authors: John D. Hainsworth (14 shared papers)Jeffrey R. Infante (5 shared papers)Johanna C. Bendell (10 shared papers)Howard A. Burris (5 shared papers)Joseph R. Mace (7 shared papers)Scott S. Tykodi (12 shared papers)David R. Spigel (8 shared papers)Lowell L. Hart (6 shared papers)
Journals: Journal of Clinical Oncology (19 papers)Blood (5 papers)Annals of Oncology (4 papers)The Oncologist (3 papers)Clinical Genitourinary Cancer (3 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Edward Arrowsmith

56 papers receiving 1.1k citations

Peers

Countries citing papers authored by Edward Arrowsmith

Since Specialization

Citations

This map shows the geographic impact of Edward Arrowsmith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Arrowsmith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Arrowsmith more than expected).

Fields of papers citing papers by Edward Arrowsmith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Arrowsmith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Arrowsmith. The network helps show where Edward Arrowsmith may publish in the future.

Co-authors

The 25 scholars most cited alongside Edward Arrowsmith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Edward Arrowsmith Line = papers co-authored together Edward Arrowsmith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 60 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial Annals of Oncology ·Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh, Irfan Firdaus, P. A. Philip, Allen Lee Cohn, Nancy Lewis, D. Mark Anderson, Edward Arrowsmith, Jonathan D. Schwartz, Ling Gao, Yanzhi Hsu, Yiwen Xu, D. Ferry, Steven R. Alberts, Zev A. Wainberg	2016	98
2	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial Journal for ImmunoTherapy of Cancer ·Scott S. Tykodi, Lucio Gordan, Robert Alter, Edward Arrowsmith, Michael R. Harrison, Ivor Percent, Rakesh Singal, Peter J. Van Veldhuizen, Daniel J. George, Thomas E. Hutson, Joshua Zhang, Jesús Zoco, Jennifer L. Johansen, Arash Rezazadeh Kalebasty	2022	85
3	Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma Haematologica ·J. G. Berdeja, Lowell L. Hart, Joseph R. Mace, Edward Arrowsmith, James Essell, Rami Owera, John D. Hainsworth, Ian W. Flinn	2015	79
4	A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma Cancer Investigation ·John D. Hainsworth, Jeffrey R. Infante, David R. Spigel, Edward Arrowsmith, Ralph V. Boccia, Howard A. Burris	2011	76
5	Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer Cancer Medicine ·Andres Forero‐Torres, Jeffrey R. Infante, David Waterhouse, Lucas Wong, Selwyn M. Vickers, Edward Arrowsmith, Aiwu Ruth He, Lowell L. Hart, David Trent, James L. Wade, Xiaoping Jin, Qiang Wang, TaShara Austin, Michael Rosen, Robert A. Beckman, Reinhard von Roemeling, Jonathan Greenberg, Mansoor N. Saleh	2013	72
6	Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study The Lancet Oncology ·Toni K. Choueiri, David F. McDermott, Jaime R. Merchan, Todd M. Bauer, Robert A. Figlin, Elisabeth I. Heath, M. Dror Michaelson, Edward Arrowsmith, Anishka D'souza, Zhao Song, Ananya Roy, Rodolfo F. Perini, Donna Vickery, Scott S. Tykodi	2023	64
7	Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. Journal of Clinical Oncology ·Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh, Irfan Firdaus, Philip Agop Philip, Allen Lee Cohn, Nancy Lewis, D. Mark Anderson, Edward Arrowsmith, Jonathan D. Schwartz, Yihuan Xu, Minori Koshiji, Steven R. Alberts, Zev A. Wainberg	2014	64
8	A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC) Targeted Oncology ·John D. Hainsworth, James A. Reeves, Joseph R. Mace, Edward Crane, Oday Hamid, John R. Stille, Amy Flynt, Stephanie Roberson, John Polzer, Edward Arrowsmith	2016	54
9	Peripheral T-cell Lymphomas: Clinical Features and Prognostic Factors of 92 Cases Defined by the Revised European American Lymphoma Classification Leukemia & lymphoma ·Edward Arrowsmith, William R. Macon, Marsha C. Kinney, Richard S. Stein, Stacey Goodman, David Morgan, John M. Flexner, John B. Cousar, Madan Jagasia, Thomas L. McCurley, John P. Greer	2002	53
10	Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens Clinical Cancer Research ·Kimmie Ng, Josep Tabernero, Jimmy J. Hwang, Emilio Bajetta, Sunil Sharma, Salvatore A. Del Prete, Edward Arrowsmith, David P. Ryan, Michaela Šedová, Jin Jin, Kamel Malek, Charles S. Fuchs	2013	53
11	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC Journal of Thoracic Oncology ·Roy S. Herbst, Hendrik Tobias Arkenau, Johanna C. Bendell, Edward Arrowsmith, Martin Wermke, A. Segado Soriano, Nicolas Penel, Rafael Santana-Dávila, Helge Bischoff, Ian Chau, Gu Mi, Hong Wang, Erik Rasmussen, David Ferry, Bo H. Chao, Luis Paz‐Ares	2020	44
12	Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer Clinical Colorectal Cancer ·David R. Spigel, Johanna C. Bendell, Michael McCleod, Dianna Shipley, Edward Arrowsmith, Edward K. Barnes, Jeffrey R. Infante, Howard A. Burris, F. Anthony Greco, John D. Hainsworth	2011	37
13	Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial Clinical Genitourinary Cancer ·John D. Hainsworth, Mark S. Rubin, Edward Arrowsmith, James Khatcheressian, Edward Crane, Luís Franco	2013	31
14	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920 Cancer ·Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson, Edward Arrowsmith, Joshua Zhang, Jesús Zoco, Jennifer L. Johansen, David Leung, Scott S. Tykodi	2021	31
15	Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study Clinical Genitourinary Cancer ·Joshua J. McFarlane, Mark D. Kochenderfer, Mark R. Olsen, Todd M. Bauer, Ana M. Molina, Ralph J. Hauke, James A. Reeves, Sunil Babu, Peter J. Van Veldhuizen, Bradley G. Somer, Vijay Gunuganti, Ian D. Schnadig, Saby George, Ray D. Page, Edward Arrowsmith, Rohit Jain, Joshua Zhang, M. Brent McHenry, Jennifer L. Johansen, Nicholas J. Vogelzang	2020	29
16	Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology ·Toni K. Choueiri, Todd M. Bauer, David F. McDermott, Edward Arrowsmith, Ananya Roy, Rodolfo F. Perini, Donna Vickery, Scott S. Tykodi	2021	27
17	Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium Clinical Breast Cancer ·Denise A. Yardley, Howard A. Burris, Bobby L. Clark, Dianna Shipley, Mark A. Rubin, John H. Barton, Edward Arrowsmith, John D. Hainsworth	2011	24
18	Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis. Journal of Clinical Oncology ·John D. Hainsworth, Edward Arrowsmith, Michael McCleod, Luis Fayad, Oday Hamid, Lara E. Davis, Boris K. Lin	2011	18
19	Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma Melanoma Research ·Ralph J. Hauke, Jeffrey R. Infante, Mark S. Rubin, Kent C. Shih, Edward Arrowsmith, John D. Hainsworth	2013	15
20	A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort American Journal of Hematology ·Jesús G. Berdeja, Tara Gregory, Edward A. Faber, Lowell L. Hart, Joseph R. Mace, Edward Arrowsmith, Ian W. Flinn, Jeffrey Matous	2021	13

About Edward Arrowsmith

Edward Arrowsmith is a scholar working on Oncology, Hematology, Pulmonary and Respiratory Medicine, Cancer Research and Applied Microbiology and Biotechnology, having authored 60 papers that have together received 1.2k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (18 papers), Cancer Immunotherapy and Biomarkers (15 papers), Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (9 papers), Renal and related cancers (9 papers), Cancer Genomics and Diagnostics (7 papers), Colorectal Cancer Treatments and Studies (5 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Oncology (623 citations), Pulmonary and Respiratory Medicine (536 citations), Cancer Research (234 citations), Gastroenterology (63 citations) and Hematology (117 citations). Edward Arrowsmith has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include John D. Hainsworth, Jeffrey R. Infante, Johanna C. Bendell, Howard A. Burris, Joseph R. Mace, Scott S. Tykodi, David R. Spigel, Lowell L. Hart, Ian W. Flinn and Ralph V. Boccia. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, The Oncologist and Clinical Genitourinary Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact